Patents Assigned to Array Biopharma Inc.
  • METHODS OF SYNTHESIS OF BENZAZEPINE DERIVATIVES
    Publication number: 20100216989
    Abstract: The disclosure describes method of synthesis of substituted benzazepine derivatives. Preferred methods according to the disclosure allow for large-scale preparation of benzazepine compounds having low levels of metal impurities. In some embodiments, preferred methods according to the disclosure also allow for the preparation of benzazepine derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. The methods disclosed herein find utility in synthetic organic chemistry as well as medicinal chemistry.
    Type: Application
    Filed: November 6, 2009
    Publication date: August 26, 2010
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: J. Jeffry Howbert, Venkat R. Kusukuntla, Alexander Tretyakov, Nathan Nielsen, Pavel Krasik, Ji-Long Jiang, Hong Woon Yang
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 7777050
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: August 17, 2010
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 7777032
    Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: August 17, 2010
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus
    Publication number: 20100204240
    Abstract: Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein.
    Type: Application
    Filed: September 15, 2008
    Publication date: August 12, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Jay Bradford Fell, John P. Fischer, Indrani W. Gunawardana, Ronald Jay Hinklin, Ajay Singh, Timothy M. Tumer, Eli M. Wallce
  • Bicyclic inhibitors of MEK and methods of use thereof
    Patent number: 7772234
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R8, R9 and R10, W, X, and Z are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 10, 2010
    Assignee: Array Biopharma Inc.
    Inventors: Eli Wallace, Hong Woon Yang, James Blake
  • 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES
    Publication number: 20100173955
    Abstract: Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Application
    Filed: August 21, 2007
    Publication date: July 8, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: George Doherty, Adam Cook
  • PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
    Publication number: 20100145065
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Application
    Filed: June 21, 2006
    Publication date: June 10, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20100144751
    Abstract: Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
    Type: Application
    Filed: March 27, 2008
    Publication date: June 10, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Fredrik P. Marmsater, Mark C. Munson, James P. Rizzi, John E. Robinson, Stephen T. Schlacter, George T. Topalov, Joseph P. Lyssikatos
  • Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
    Patent number: 7732616
    Abstract: Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: June 8, 2010
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • SNAR PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
    Publication number: 20100130748
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X1, X2, X5, R1, R2 and R4 are as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Application
    Filed: June 21, 2006
    Publication date: May 27, 2010
    Applicants: ARRAY BIOPHARMA INC., ASTRAZENECA AB
    Inventors: John Demattei, Sagar Shakya, Paul J. Nichols, Bradley R. Barnett, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, John Leonard
  • Heterobicyclic pyrazole compounds and methods of use
    Patent number: 7723330
    Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: May 25, 2010
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Steven Armen Boyd, Jason De Meese, Kin Chiu Fong, John J. Gaudino, Tomas Kaplan, Allison L. Marlow, Jeongbeob Seo, Allen A. Thomas, Hongqi Tian, Frederick Cohen, Wendy B. Young
  • Method of Treatment Using Inhibitors of Mitosis
    Publication number: 20100099697
    Abstract: Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 22, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Brian J. Tunquist, Duncan H. Walker, Richard D. Woessner
  • 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS
    Publication number: 20100099713
    Abstract: Provided are compounds having the Formula I or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Application
    Filed: January 16, 2008
    Publication date: April 22, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Thomas Daniel Aicher, Steven Armen Boyd, Mark Joseph Chicarelli, Kevin Ronald Condroski, Rustam Ferdinand Garrey, Ronald Jay Hinklin, Ajay Singh, Timothy M. Turner
  • RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20100063066
    Abstract: Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: August 31, 2007
    Publication date: March 11, 2010
    Applicant: Array Biopharma, Inc.
    Inventors: Alexandre J. Buckmelter, Joseph P. Lyssikatos, Greg Miknia, Li Ren, Steven Mark Wenglowsky, Bryson Rast
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
    Publication number: 20100063053
    Abstract: Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 12, 2009
    Publication date: March 11, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • GLUCOKINASE ACTIVATORS
    Publication number: 20100056530
    Abstract: Provided are compounds of Formula I wherein R1, R2, Y, Z and G are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Application
    Filed: October 24, 2006
    Publication date: March 4, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Thomas D. Aicher, Wai-man Lee, Ronald Jay Hinklin, Mark Joseph Chicarelli, Steven Armen Boyd, Kevin Ronald Condroski
  • MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20100041719
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.
    Type: Application
    Filed: October 3, 2007
    Publication date: February 18, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Kateri Ahrendt, Robert Kirk Delisle, Jeremy Hans, Joseph P. Lyssikatos, John E. Robinson, Eli M. Wallace, Qian Zhao
  • IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20100029633
    Abstract: Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
    Type: Application
    Filed: March 27, 2008
    Publication date: February 4, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Shelley Allen, Julie Marie Greschuk, Nicholas C. Kallan, Fredrik P. Marmsãter, Mark C. Munson, James P. Rizzi, John E. Robinson, Stephen T. Schlachter, George T. Topalov, Qian Zhao, Joseph P. Lyssikatos
  • NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20090297476
    Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: May 9, 2008
    Publication date: December 3, 2009
    Applicants: InterMune, Inc., Array Biopharma Inc.
    Inventors: SCOTT SEIWERT, STEVEN W. ANDREWS, LEONID BEIGELMAN, LAWRENCE M. BLATT, BRAD BUCKMAN, Kevin R. Condroski, Yutong Jiang, Robert J. Kaus, April L. Kennedy, Timonthy S. Kercher, Michael A. Lyon, Bin Wang
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20090270621
    Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: July 2, 2009
    Publication date: October 29, 2009
    Applicant: ARRAY BIOPHARMA, INC.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao